| Literature DB >> 24404157 |
Priyanka Dhar1, Vijay K Sharma1, Kalpana B Hota1, Saroj K Das1, Sunil K Hota1, Ravi B Srivastava1, Shashi B Singh2.
Abstract
Acute exposure to hypobaric hypoxia at high altitude is reported to cause sympathetic dominance that may contribute to the pathophysiology of high altitude illnesses. The effect of prolonged stay at high altitude on autonomic functions, however, remains to be explored. Thus, the present study aimed at investigating the effect of high altitude on autonomic neural control of cardiovascular responses by monitoring heart rate variability (HRV) during chronic hypobaric hypoxia. Baseline electrocardiography (ECG) data was acquired from the volunteers at mean sea level (MSL) (<250 m) in Rajasthan. Following induction of the study population to high altitude (4500-4800 m) in Ladakh region, ECG data was acquired from the volunteers after 6 months (ALL 6) and 18 months of induction (ALL 18). Out of 159 volunteers who underwent complete investigation during acquisition of baseline data, we have only included the data of 104 volunteers who constantly stayed at high altitude for 18 months to complete the final follow up after 18 months. HRV parameters, physiological indices and biochemical changes in serum were investigated. Our results show sympathetic hyperactivation along with compromise in parasympathetic activity in ALL 6 and ALL 18 when compared to baseline data. Reduction of sympathetic activity and increased parasympathetic response was however observed in ALL 18 when compared to ALL 6. Our findings suggest that autonomic response is regulated by two distinct mechanisms in the ALL 6 and ALL 18. While the autonomic alterations in the ALL 6 group could be attributed to increased sympathetic activity resulting from increased plasma catecholamine concentration, the sympathetic activity in ALL 18 group is associated with increased concentration of serum coronary risk factors and elevated homocysteine. These findings have important clinical implications in assessment of susceptibility to cardio-vascular risks in acclimatized lowlanders staying for prolonged duration at high altitude.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24404157 PMCID: PMC3880292 DOI: 10.1371/journal.pone.0084274
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Baseline characteristics of volunteers included in the study.
| Level 1 (L1) Criteria | |
| Parameter | Criteria |
|
| |
| Age (years) | 23–35 |
| Gender | Male |
| Education (years) | 12±2 |
| Monthly earnings (INR) | 18000±2500 |
|
| |
| Any serious health illnesses | NA |
| Head injury resulting in loss of consciousness | NA |
| Any form of seizures, delirium tremens or convulsions | NA |
| Heart attack or any heart problem | NA |
| Cancer | NA |
| Allergies to medications, foods, animals, chemicals, or other agent | NA |
| Lung diseases such as asthma, emphysema, or chronic bronchitis | NA |
| Surgeries or hospitalizations | NA |
| Hypertension | NA |
| Diabetes | NA |
| Viral Hepatitis | NA |
| Dementia/Memory Impairment | NA |
| Stroke/Infarction/Cerebral Hemorrhage | NA |
| Kidney Disease | NA |
| GERD symptoms | NA |
| Chest Pain | NA |
| Congenital Heart Disease | NA |
| Neurological Problem/Epilepsy | NA |
| Familial Disorders | NA |
|
| |
|
|
|
|
| Non-alcoholics |
|
| Non-smokers |
|
| Vegetarian and non-vegetarian |
|
| Mild to moderate |
|
| 4.85±3.96 |
*Plus-minus values are mean ± SD; NA indicates not applicable.
Figure 1Study profile: Flow chart of the volunteers depicting recruitment, assessment and retention in the study.
Physiological measures of the study groups (n = 104).
| Normal range | Baseline | ALL 6 | ALL 18 | |
| SBP (mm Hg) | 110–130 | 120.86±0.58 | 123.18±0.72 | 123.05±0.80 |
| DBP (mm Hg) | 75–85 | 80.02±0.34 | 82.72±0.70 | 81.99±0.83 |
| Pulse Rate (BPM) | 70–80 | 71.76±0.51 | 85.17±1.12* | 80.22±1.20*# |
| SpO2 (%) | 95–98 | 96.44±0.09 | 89.18±0.20* | 91.69±0.35*# |
| BMI | 18.50–24.90 | 21.78±0.12 | 21.84±0.14 | 22.02±0.24 |
Values indicated are means ± SEM.
P<0.05: * compared with Baseline; # compared with ALL 6.
SBP: systolic blood pressure; DBP: diastolic blood pressure; SpO2: hemoglobin oxygen saturation; BMI: body mass index.
Heart rate variability indices of the study groups (n = 104).
| Baseline | ALL 6 | ALL 18 | |
|
| |||
| Mean RR (s) | 0.792±0.010 | 0.671±0.010* | 0.718±0.008*# |
| SDNN (s) | 0.049±0.002 | 0.032±0.001* | 0.042±0.001*# |
| RR TI | 0.123±0.004 | 0.059±0.003* | 0.087±0.001*# |
| TINN (ms) | 351.63±15.92 | 202.58±8.14* | 292.76±6*# |
| TP ms2 | 1566.58±94.60 | 748.42±43.62* | 996.05±29.13*# |
|
| |||
| Mean HR (1/min) | 77.44±0.88 | 90.24±0.98* | 85.65±0.98*# |
| LF power ms2 | 671.68±34.28 | 412.18±23.11* | 530.36±16.81*# |
| LF (nu) | 59.06±0.98 | 80.12±0.76* | 69.39±1.19*# |
|
| |||
| RMSSD (ms) | 39.01±2.74 | 21.10±0.89* | 32.24±0.56*# |
| NN50 (count) | 106.15±8.72 | 30.12±3.84* | 71.61±2.98*# |
| pNN50 (%) | 17.72±1.50 | 5.80±0.44* | 11.15±0.90*# |
| SD1 (ms) | 34.82±1.95 | 15.70±0.72* | 24.99±0.57*# |
| HF power ms2 | 468.88±36.92 | 185.82±15.74* | 289.12±8.73*# |
| HF (nu) | 34.51±0.98 | 16.40±0.91* | 24.59±0.66*# |
|
| |||
| LF/HF | 2.21±0.08 | 3.62±0.18* | 3.07±0.11*# |
|
| 11.70±0.07 | 13.17±0.10* | 13.22±0.11* |
Values indicated are means ± SEM.
P<0.05: * compared with Baseline; # compared with ALL 6.
Mean RR: mean RR interval; SDNN: standard deviation of RR intervals; RMSSD: root mean square of the differences between consecutive RR intervals; NN50: number of consecutive RR intervals differing more than 50 ms; pNN50: percentage value of NN50 intervals; RRTI: RR triangular index; TINN: triangular index of normal to normal intervals; VLF: very low frequency; LF: low frequency; HF: high frequency.
Hemoglobin, hematocrit, kidney and liver function profiling of the study groups (n = 104).
| Reference range | Baseline | ALL 6 | ALL 18 | |
| Hb (g/dL) | 13.80–17.20 | 15.28±0.07 | 17.78±0.06* | 18.47±0.11*# |
| Hct (%) | 43–52 | 46.88±0.17 | 53.56±0.22* | 55.34±0.29*# |
| BUN(ng/ml) | 6–20 | 9.22±0.24 | 9.38±0.23 | 9.42±0.25 |
| Creatinine (ng/ml) | 0.90–1.30 | 0.910±0.012 | 0.928±0.014 | 0.930±0.015 |
| ALT (ng/ml) | 30–65 | 43.12±0.81 | 44.19±1.02 | 43.46±1.39 |
| AST (ng/ml) | 15–37 | 29.22±0.28 | 29.50±0.40 | 29.90±1.25 |
Values indicated are means ± SEM.
P<0.05: * compared with Baseline; # compared with ALL 6.
Hb: Hemoglobin; Hct: Hematocrit; BUN: blood urea nitrogen; HDL: high density lipoprotein; LDL: low density lipoprotein; VLDL: very low density lipoprotein; ALT: alanine aminotransferase; AST: aspertate aminotransferase.
Serum coronary risk factor profiling of the study groups (n = 104).
| Reference range | Baseline | ALL 6 | ALL 18 | |
| Cholesterol (mg/dl) | <200 | 124.38±0.88 | 139.84±2.30 | 151.52±4.16 |
| Triglycerides (mg/dl) | <150 | 81.22±1.80 | 98.54±2.85 | 129.46±7.36 |
| HDL (mg/dl) | 40–60 | 45.87±0.64 | 39.07±0.88 | 35.30±0.44 |
| LDL (mg/dl) | <100 | 78.73±0.85 | 89.30±2.16 | 104.45±2.40*# |
| Cholesterol/HDL | 3.30–4.40 | 2.98±0.03 | 3.64±0.07 | 4.47±0.08*# |
| LDL/HDL | 0.50–3.0 | 1.92±0.03 | 2.37±0.07 | 3.27±0.08*# |
| VLDL (mg/dl) | ≤30 | 15.98±0.42 | 19.12±0.86 | 26.50±1.17 |
| Homocysteine (µmol/ml) | 3.70–13.90 | 9.12±0.07 | 17.48±0.09* | 22.97±1.18*# |
| Vitamin B12 (pg/mI) | 211–911 | 262.82±3,78 | 224.81±3.86 | 213.70±5.37 |
| Folic Acid (ng/ml) | >5.38 | 7.92±0.14 | 6.22±0.15 | 5.77±0.19 |
Values indicated are means ± SEM.
P<0.05: * compared with Baseline; # compared with ALL 6.
Hb: hemoglobin; Hct: hematocrit; BUN: blood urea nitrogen; HDL: high density lipoprotein; LDL: low density lipoprotein; VLDL: very low density lipoprotein; ALT: alanine aminotransferase; AST: aspertate aminotransferase.
Figure 2Graphic representation of serum coronary risk factor profile in baseline and follow up groups.
The limits of the boxes represent the middle 50% of the data values; the extent of the lines encompass the interquartile range with extreme outlying data points shown as such. The central line within each box represents the median. a. Serum LDL concentration is significantly elevated in ALL 18 (P<0.05) vs Baseline. b. Serum cholesterol/HDL ratio is significantly elevated in ALL 18 (P<0.05) vs Baseline. c. Serum LDL/HDL ratio is significantly elevated in ALL 18 (P<0.05) vs Baseline. d. Serum homocysteine concentration is significantly elevated in ALL 18 (P<0.05) vs Baseline.
Figure 3Concentration of a. Serum ACE (ng/ml) and b. Serum angiotensin II (pg/ml) in baseline and follow ups.
Figure 4Plasma norepinephrine and epinephrine concentration (pg/ml) in baseline and follow ups.
Plasma norepinephrine and epinephrine concentration are significantly elevated in ALL 6 vs Baseline and ALL 18. P<0.05: * compared with Baseline; # compared with ALL 18.